Pneumococcal Vaccine Market Segmentation:
Vaccine Type Segment Analysis
The PCV20 segment of the vaccine type segment is expected to hold the highest share of 70% in the market by the end of 2035. The global shift toward cost-effective and preventive care is the basic growth driver behind this. Several clinical studies have also proved the extensive clinical advantages of using this subtype as an alternative to PCV13 and PCV15. As per a report by CDC, September 2024, in adults aged ≥65 years, PCV20 was shown to meet noninferiority criteria for all 13 shared serotypes compared with PCV13. As a result, PCV20 has become the most preferred option for both healthcare professionals and patients.
Age Group Segment Analysis
Based on the age group, the pediatric segment is anticipated to lead the market throughout the forecast period. The requirement of immunization for young children, ensuring their protection from potentially life-threatening conditions, such as pneumonia, meningitis, and blood infections, is a major factor in the segment's dominance. As a result, the involvement of both private and public organizations in advocating and managing vaccination for this age group is highly engaged. Their continuous participation and support further reinforce the expansion of this segment. As per a report by NLM in December 2023, global coverage of the final dose of PCV was only 51% in the last 4 years, highlighting the continued need for equitable distribution and education.
Distribution Channel Segment Analysis
The public health segment is expected to hold the highest share of the distribution channel segment in the market by 2035. This dominance could primarily be attributed to large-scale immunization programs implemented by government bodies and international health organizations such as WHO, Gavi, and UNICEF to improve access to and affordability of vaccines in low- and middle-income countries through public procurement and donor funding schemes. In addition, national immunization schedules, which include pneumococcal vaccines for routine childhood and adult vaccination, add to the clout of the public sector.
Our in-depth analysis of the global market includes the following segments:
|
Segment |
Subsegments |
|
Product |
|
|
Vaccine Type |
|
|
Age Group |
|
|
Distribution Channel |
|
|
Region |
|
